​Saros Therapeutics

Saros Therapeutics develops novel medicines to Improve Outcomes for patients with cancer. By harnessing the STING pathway with Saros' lipid nanoparticle technology, the limitations of prior STING agonists are significantly overcome. In combination with existing immunotherapies, this approach may enable a safe, effective immune response against tumors

32 Biosciences​

32 Biosciences is focused on gastrointestinal (GI) diseases—initially centered on the colon—addressing high unmet medical needs in prevention and treatment with a first-in-class therapeutic and a novel discovery platform.
A compromised gastrointestinal mucosal barrier is associated with increased infection risk, chronic disease, and microbiome imbalance. To prevent and treat disease, we are restoring and protecting the GI mucosal-immune system while building a proprietary GI discovery platform.
  • CS Therapeutic Pipeline — a Mucosal Immune Modulator (MIM) therapeutic approach that restores and protects the mucosal-immune barrier in the gastrointestinal tract (lead asset: CS-0003).
  • GB: GI Discovery Platform — quantifies metabolomic signatures of the gut mucosal-immune system to enable therapeutic discovery, development, and clinical decision support.
Our mission is to prevent and treat severe GI diseases by restoring and protecting the GI mucosal-immune system, advancing our therapeutic pipeline, and expanding our GI discovery platform.

bionode

Through developing a first-in-class smartlens system that rapidly reduces intraocular pressure in glaucoma patients, bionode seeks to enhance glaucoma therapy and improve patient outcomes. The smartlens - called IOPTx - has proven success in clinical trials,  reducing intraocular pressure in patients by 38%.

Cadenza Bio

Still in the preclinical stage, Cadenza Bio is developing orally available small molecule drugs to promote remyelination and limit inflammation in patients with Multiple Mclerosis (MS).  Their highly selective, non-steroidal agonists of Estrogen Receptor β (ERβ) harness the beneficial
neuroprotective and anti-inflammatory impacts of estrogen without risking feminization or proliferation associated with Estrogen Receptor α (ERα).

Delphian Therapeutics

Delphian Therapeutics is a clinical-stage company, unlocking the full therapeutic potential of endocannabinoid system modulation to treat large, poorly managed pain and neurological disorders.

Funded by the U.S. National Institutes of Health, we are leveraging the science of natural cannabinoids to develop optimized medicines for FDA and EMA approval, starting with migraine.
Picture

Atzeyo

Our mission is to change the lives of cancer patients by transforming their journey.  We have created a unique diagnostic platform designed specifically for specialty physician and oncologist offices.  We have successfully brought together the speed and cost of point-of-care platforms combined with the accuracy and quality of core lab instruments. The platform will allow physicians to diagnose while their patient is in office eliminating extra office visits for the patient and accelerating the path to treatment.​